S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Asian benchmarks trade mixed amid expectations for US rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
NASDAQ:KMDA

Kamada (KMDA) Stock Price, News & Analysis

$4.90
-0.22 (-4.30%)
(As of 04/16/2024 ET)
Today's Range
$4.90
$5.12
50-Day Range
$4.90
$6.42
52-Week Range
$4.08
$6.53
Volume
108,044 shs
Average Volume
23,714 shs
Market Capitalization
$281.60 million
P/E Ratio
32.67
Dividend Yield
N/A
Price Target
$11.00

Kamada MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
124.5% Upside
$11.00 Price Target
Short Interest
Healthy
0.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.07mentions of Kamada in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
78.26%
From $0.23 to $0.41 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.15 out of 5 stars

Medical Sector

154th out of 930 stocks

Pharmaceutical Preparations Industry

57th out of 419 stocks

KMDA stock logo

About Kamada Stock (NASDAQ:KMDA)

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Stock Price History

KMDA Stock News Headlines

Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 10.4% in March
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
KMDA Aug 2024 10.000 call
KMDA May 2024 5.000 call
KMDA Apr 2024 10.000 call
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
Preview: Kamada's Earnings
Kamada: Q4 Earnings Snapshot
Kamada Issues 2024 CEO Letter to Shareholders
Kamada Ltd.
3 Pharma Gems Driving Profits Now
Will These 3 Pharma Stocks Become Gainers in 2024?
Kamada: Kedrion Deal Locks In Growth
See More Headlines
Receive KMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/16/2024
Next Earnings (Estimated)
5/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KMDA
Employees
378
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+124.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$8.28 million
Pretax Margin
5.91%

Debt

Sales & Book Value

Annual Sales
$142.52 million
Cash Flow
$0.41 per share
Book Value
$4.25 per share

Miscellaneous

Free Float
36,726,000
Market Cap
$281.60 million
Optionable
Optionable
Beta
1.04
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Amir London (Age 55)
    Chief Executive Officer
    Comp: $611k
  • Mr. Chaime Orlev (Age 54)
    Chief Financial Officer
    Comp: $387k
  • Mr. Eran Nir (Age 51)
    Chief Operating Officer
    Comp: $332k
  • Mr. Jon R. Knight (Age 58)
    Vice President of US Commercial Operations
    Comp: $307k
  • Mr. Boris Gorelik (Age 43)
    Vice President of Business Development & Strategic Programs
    Comp: $410k
  • Mr. David Tsur (Age 74)
    Co-Founder & Independent Deputy Chairman of the Board
    Comp: $252k
  • Mr. Nir Livneh B.A. (Age 44)
    L.L.B., VP, General Counsel & Corporate Secretary
  • Ms. Hanni Neheman (Age 54)
    Vice President of Marketing & Sales
  • Ms. Liron Reshef (Age 52)
    Vice President of Human Resources
  • Ms. Shavit Beladev
    Vice President of Kamada Plasma

KMDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kamada stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" KMDA shares.
View KMDA analyst ratings
or view top-rated stocks.

What is Kamada's stock price target for 2024?

1 analysts have issued 12-month price targets for Kamada's stock. Their KMDA share price targets range from $11.00 to $11.00. On average, they expect the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 124.5% from the stock's current price.
View analysts price targets for KMDA
or view top-rated stocks among Wall Street analysts.

How have KMDA shares performed in 2024?

Kamada's stock was trading at $6.12 at the beginning of 2024. Since then, KMDA shares have decreased by 19.9% and is now trading at $4.90.
View the best growth stocks for 2024 here
.

Are investors shorting Kamada?

Kamada saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 40,300 shares, a decrease of 10.4% from the March 15th total of 45,000 shares. Based on an average daily volume of 23,000 shares, the short-interest ratio is presently 1.8 days. Approximately 0.1% of the company's shares are short sold.
View Kamada's Short Interest
.

When is Kamada's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 22nd 2024.
View our KMDA earnings forecast
.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) posted its earnings results on Wednesday, March, 6th. The biotechnology company reported $0.09 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.04. The biotechnology company earned $36.43 million during the quarter, compared to the consensus estimate of $37.71 million. Kamada had a net margin of 5.81% and a trailing twelve-month return on equity of 5.66%.

What guidance has Kamada issued on next quarter's earnings?

Kamada issued an update on its FY 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $156.0 million-$160.0 million, compared to the consensus revenue estimate of $166.1 million.

What other stocks do shareholders of Kamada own?
How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KMDA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners